VYGR - Voyager Therapeutics, Inc.
| Previous Close | 18.53 |
| Open | 18.69 |
| Bid | 0.00 x 0 |
| Ask | 20.33 x 200 |
| Day's Range | 17.66 - 19.05 |
| 52 Week Range | 8.10 - 31.91 |
| Volume | 602,810 |
| Avg. Volume | 463,717 |
| Market Cap | 578.112M |
| Beta | 3.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.64 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.46 |
Market Realist•6 days agoAnalysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
- Market Realist•11 days ago
Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.
Market Realist•11 days agoInsight into the Financial Performance of Voyager Therapeutics
In the future, Voyager is expected to earn collaboration revenues from Sanofi and AbbVie. This increase of $20 million was primarily attributable to a jump in external research costs and employee expenses. Its external research costs rose from $20.4 million in 2016 to $33.8 million in 2017.
- Market Realist•11 days ago
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases. It focuses on those neurological diseases for which an adeno-associated virus (or AAV) gene therapy can reduce the symptoms experienced by patients. Of the 13 analysts covering Voyager Therapeutics in April 2018, five have given the stock “strong buy” ratings, five have given it “buy” ratings, and three have given it “hold” ratings.
- Market Realist•11 days ago
Exploring Voyager Therapeutics’ Research Pipeline
Voyager Therapeutics’ (VYGR) research pipeline consists of six programs targeting different neurological indications, including advanced Parkinson’s disease, amyotrophic lateral sclerosis (or ALS), Huntington’s disease, and Alzheimer’s disease. Voyager Therapeutics’ most advanced clinical candidate is VY-AADC for the treatment of advanced Parkinson’s disease.
- TheStreet.com•26 days ago
4 Strong Buy Biotech Stocks Poised to Explode
Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.
- Associated Press•last month
Voyager Therapeutics reports 4Q loss
The Cambridge, Massachusetts-based company said it had a loss of 40 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
VY-AADC for advanced Parkinson’ s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year. Two IND filings expected from the ALS, Huntington’ s disease and ...
- Zacks•last month
Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
- ACCESSWIRE•last month
Wired News – Voyager Therapeutics Declared Longer-term Data from Phase-1b Trial Of VY-AADC for Advanced Parkinson’s Disease
Stock Monitor: Editas Medicine Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
- GlobeNewswire•2 months ago
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’ s disease medications; one-time administrations of VY-AADC ...
- GlobeNewswire•2 months ago
Recent Analysis Shows Mobile Mini, Corindus Vascular Robotics, Payment Data, STAAR Surgical, Voyager Therapeutics, and Sunshine Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
Voyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call
CAMBRIDGE, Mass., Feb. 27, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its fourth quarter ...
- GlobeNewswire•2 months ago
Voyager Therapeutics to Present at Cowen Health Care Conference
CAMBRIDGE, Mass., Feb. 26, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation ...
- Motley Fool•2 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can the momentum continue for these hot biotech stocks?
- Zacks•2 months ago
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
- ACCESSWIRE•2 months ago
Wired News – Voyager Therapeutics Signs Global Collaboration Agreement with AbbVie to Develop New Treatments for Tau-Related Neuro-Degenerative Diseases
Stock Monitor: Bioverativ Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR ...
- Investor's Business Daily•2 months ago
How An AbbVie Deal Sent This Biotech Stock To A 2-Year High
Voyager continued rocketing Wednesday after announcing a collaboration with AbbVie to develop an Alzheimer's disease drug.
- Market Exclusive•2 months ago
Here’s What The AbbVie and Voyager Therapeutics Deal Really Means
AbbVie (NYSE:ABBV) and Voyager Therapeutics, Inc. (NASDAQ:VYGR) are big movers in the biotechnology space during the middle of this week, with the two companies putting out some potentially game-changing news (and the news is interrelated – more on this shortly) and picking up some action in their market capitalization on the back of the development. […] The post Here’s What The AbbVie and Voyager Therapeutics Deal Really Means appeared first on Market Exclusive.
- Motley Fool•2 months ago
Why Noble Energy, Voyager Therapeutics, and NXP Semiconductors Jumped Today
Find out which of these stocks made a sweet deal.
- American City Business Journals•2 months ago
Cambridge's Voyager, AbbVie to pursue Alzheimer's gene therapy under $69M deal
Voyager Therapeutics said Tuesday that it will work with AbbVie to develop gene therapy treatments for Alzheimer’s disease in a deal worth at least $69 million for the Cambridge biotech. The announcement by Voyager (VYGR) and Chicago-based AbbVie (ABBV) comes as drug developers are exploring new approaches to Alzheimer’s following a string of recent clinical setbacks. Gene therapies — drugs that work by inserting healthy genes into a person’s cells to replace faulty or missing ones — offer one intriguing avenue.
- PR Newswire•2 months ago
AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's Disease and Other Tau-Related Neurodegenerative Diseases
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. This collaboration combines AbbVie's monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager's gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.
- GlobeNewswire•2 months ago
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau. Voyager to receive $69 million upfront payment and potentially ...
- GlobeNewswire•2 months ago
Voyager Therapeutics to Present at Leerink Partners Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 07, 2018-- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced its presentation ...
- Benzinga•3 months ago
Morgan Stanley Says Parkinson's Candidate Makes Voyager Therapeutics A Buy
Voyager Therapeutics Inc (NASDAQ: VYGR ) faded this week on news of a CEO transition, but the firm caught a boost Friday from a new advocate. The Rating Morgan Stanley analyst Matthew Harrison initiated ...
